Prediction of Sinensetin from Kumis Kucing (Orthosiphon aristatus) as Aspulvinone Dimethylallyltransferase Inhibitor for Anticancer Agent
DOI:
https://doi.org/10.64123/mijm.v1.i1.3Keywords:
Sinensetin, Orthosiphon aristatus, Aspulvinone Dimethylallyltransferase, Anticancer, In Silico PredictioAbstract
Sinensetin, a polymethoxylated flavone found in Orthosiphon aristatus (commonly known as Kumis Kucing), was evaluated in silico for its potential inhibitory activity against Aspulvinone Dimethylallyltransferase, an enzyme implicated in cancer-related biosynthetic pathways. The SMILES structure of sinensetin was retrieved from PubChem and analyzed using the PASS online prediction tool (www.way2drug.com). The results showed a high probability of activity (Pa = 0.865) and a very low probability of inactivity (Pi = 0.016), indicating that sinensetin is likely to act as a potent inhibitor of the enzyme. These findings suggest that sinensetin could be a promising anticancer agent candidate by targeting Aspulvinone Dimethylallyltransferase. Further studies are recommended to validate this prediction through molecular docking and biological assays.
Downloads
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Fendy Prasetyawan, Chandra Arifin, Widhi Astutik, Eka Hayati Rohmah, Mujtahid Bin Abd Kadir, M Wahyu Ariawan, Yogi Bhakti Marhenta, Ratna Mildawati, Yuneka Saristiana, Abd Rofiq (Author)

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All articles published in this journal are licensed under the terms of the Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
-
As long as appropriate credit is given to the original author(s), a link to the license is provided, and any changes made are indicated.
-
If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
License URL: https://creativecommons.org/licenses/by-sa/4.0/




















